View Older Stories View More Recent Stories

Jan 18, 2017 04:06PM Zynerba Pharma (ZYNE) Plans Offering of Common Stock
Jan 18, 2017 04:05PM Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
Jan 3, 2017 07:03AM Zynerba Pharma (ZYNE) Initiates FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 Cannabidiol
Jan 3, 2017 07:00AM Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome
Dec 8, 2016 07:00AM Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple Diseases
Dec 5, 2016 09:06AM Zynerba Pharma (ZYNE) Announces Strong ZYN002 Phase 1 in Epilepsy Patients with Focal Seizues
Dec 5, 2016 09:05AM Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society
Nov 28, 2016 07:00AM Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society
Nov 21, 2016 07:00AM Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 14, 2016 07:00AM Zynerba Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Highlights
Nov 9, 2016 07:00AM Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 2, 2016 07:00AM Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label Extension Clinical Trial for ZYN002 CBD Gel in Adult Refractory Epilepsy Patients
Oct 17, 2016 07:00AM Zynerba Pharma (ZYNE) Updates on ZYN001; Expects to Commence Phase 1 in H117
Oct 17, 2016 07:00AM Zynerba Provides Clinical Update for Lead Development Candidates – ZYN001 and ZYN002
Sep 13, 2016 04:05PM Zynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer
Sep 6, 2016 04:05PM Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
Sep 6, 2016 07:00AM Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis
Aug 11, 2016 07:15AM Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes
Aug 3, 2016 07:00AM Zynerba Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth Conference
Aug 1, 2016 07:36AM Zynerba Pharma (ZYNE) Doses First Patients in Phase 2 STAR 1 Clinical Study
Aug 1, 2016 07:00AM Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures
Jul 6, 2016 07:00AM Zynerba Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
Jun 27, 2016 04:07PM Zynerba Pharma (ZYNE) Reports Positive Top Line Results from ZYN002 CBD Gel Phase 1, Plans Phase 2 Study
Jun 27, 2016 04:05PM Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seiz
Jun 1, 2016 07:00AM Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences
May 12, 2016 07:00AM Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights
Apr 12, 2016 07:00AM Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid
Mar 14, 2016 07:00AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights
Mar 7, 2016 07:00AM Zynerba Pharmaceuticals to Present at 28th Annual ROTH Conference
Feb 25, 2016 11:26AM CORRECTING and REPLACING -- Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome
Feb 25, 2016 10:37AM Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome
Jan 6, 2016 04:12PM Zynerba (ZYNE) Reports Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial, Initiates of Phase 1 Multiple Rising Dose Trial
Jan 6, 2016 04:01PM Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial
Nov 24, 2015 07:00AM Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 16, 2015 07:00AM Zynerba Pharmaceuticals Appoints Warren D. Cooper Lead Independent Director
Nov 11, 2015 04:05PM Zynerba Pharmaceuticals Reports Third Quarter 2015 Financial Results and Operational Highlights
Nov 11, 2015 07:00AM Zynerba Pharmaceuticals to Present at Jefferies Autumn 2015 Global Healthcare Conference
Oct 20, 2015 07:05AM Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel
Oct 7, 2015 05:03PM Zynerba Pharmaceuticals to Present at BIO Investor Forum 2015
Aug 10, 2015 11:41AM Zynerba Pharmaceuticals Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
Aug 10, 2015 11:41AM Zynerba Pharmaceuticals Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
Aug 6, 2015 07:00AM Zynerba Pharmaceuticals Builds Out Board of Directors
Aug 6, 2015 07:00AM Zynerba Pharmaceuticals Builds Out Board of Directors
Aug 4, 2015 05:57PM Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
Aug 4, 2015 05:57PM Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
View More Recent Stories View Older Stories